GSK Market Snapshot
| Price (Feb 9) | ₹2,505.50 |
| Day Change | +0.87% |
| Day Range | ₹2,475 – ₹2,540 |
| Previous Close | ₹2,484.00 |
| 52-Week Range | ₹1,968 – ₹3,515 |
GlaxoSmithKline Pharmaceuticals Limited shares were trading higher on February 9, holding gains as investors reacted to a significant regulatory milestone announced late last week. The stock was last seen at ₹2,505.50, up 0.87% on the day, as markets digested news that could meaningfully expand GSK’s respiratory franchise in Europe.
EU Approval Adds New Growth Catalyst
On February 6, GSK announced that the European Commission had approved Nucala (mepolizumab) as an add-on treatment for adults with uncontrolled eosinophilic chronic obstructive pulmonary disease (COPD), despite triple inhaled therapy. The decision marks the first approval in the European Union for a biologic targeting a broad eosinophilic COPD population.
Nucala is a once-monthly injectable biologic that targets interleukin-5 (IL-5), a key driver of eosinophilic inflammation. Until now, treatment options for this subgroup of COPD patients have been limited, making the approval a notable step in addressing a long-standing unmet medical need.
Strong Clinical Data Underpins Decision
The approval was supported by results from the MATINEE Phase III trial, which showed a 21% reduction in moderate to severe COPD exacerbations compared with placebo, alongside a 35% reduction in severe exacerbations requiring hospitalisation. The findings were published in The New England Journal of Medicine in April 2025.
Hospitalisation risk remains one of the most serious challenges in COPD management, with estimates suggesting that between 10% and 25% of patients die following admission. By lowering exacerbation severity, the therapy has the potential to reduce both clinical burden and healthcare costs across Europe.
Why the Announcement Matters for GSK Shares
COPD affects an estimated 390 million people globally, making it one of the world’s leading causes of morbidity. The EU approval positions GSK to expand Nucala’s commercial reach beyond its established asthma indications and reinforces the company’s focus on specialty medicines with durable growth potential.
The announcement also aligns with the strategic direction outlined earlier this month by GSK’s new chief executive, who has emphasised accelerating development timelines and prioritising programmes that can redefine standards of care. That broader growth plan helped lift GSK shares in London to their highest levels in more than two decades, as outlined in this Reuters report on the company’s updated outlook.
How the Stock Is Trading Today
Intraday price action on February 9 shows GSK Pharma opening near ₹2,489 before moving higher and consolidating around the ₹2,500 level. The chart reflects an early advance followed by controlled sideways trading, a pattern typically associated with measured positioning rather than short-term momentum.
At current levels, the stock carries an intraday market capitalisation of approximately ₹4.25 trillion. Valuation remains elevated, with a trailing twelve-month P/E of 44.46 and EPS of ₹56.39, reflecting expectations of steady earnings delivery rather than aggressive near-term acceleration.
Key Levels and Broader Context
Technically, the ₹2,480–₹2,500 zone continues to act as an important support area. A sustained break above ₹2,540 could reinforce bullish sentiment, while any pullback toward support is likely to be closely monitored in the wake of last week’s regulatory news.
As of February 9, GSK Pharma’s steady advance reflects cautious optimism. With a fresh EU approval strengthening its respiratory pipeline and a clearer global strategy now in place, the stock’s trajectory increasingly depends on execution, uptake, and further clinical milestones rather than short-term market swings.
